Volume : 09, Issue : 11, November – 2022
Title:
37.REVIEW ON: PATHOPHYSIOLOGY OF ARTHRITIS AND DRUGS USED IN THE MANAGEMENT OF ARTHRITIS
Authors :
Anisha A Kohale, Priya N Kothari, Anuj A Deshmukh, Amol V Sawale, Kiran L Humbarde, Shirin S Bhuyar, Riya S Bhendkar
Abstract :
Arthritis is a chronic inflammation in joints, which mostly affects the bones. In the global prevalence of joint inflammation, it’s means to be taken it as potential issues. Current treatments mostly targeting the inflammatory cytokines or effector molecules and oxidative stress involved in arthritis as pain relief temporarily. This review has mechanistically demonstrated the type of joint inflammation insights in to arthritis, such as osteoarthritis, gouty arthritis and rheumatoid arthritis to understand the clear background. This review has also highlighted the prevalence, mechanism and mediations used for arthritis, in which various causative agents are used to induce arthritis in preclinical studies that has been collectively elucidated. This review is first to be reported the mechanism of various arthritis causative agents. It pointed out the side effects of clinical medicine used for arthritis and suggested the natural products involved in medication for above-listed conditions. As comparatively natural products are low cost, easily available and beneficial than modern medicines with minimal side effects.
Keywords: Joint Inflammation, osteoarthritis, gouty arthritis, rheumatoid arthritis, natural therapeutics
Cite This Article:
Please cite this article in press Anisha A Kohale et al, Review On: Pathophysiology Of Arthritis And Drugs Used In The Management Of Arthritis., Indo Am. J. P. Sci, 2022; 09(11).
Number of Downloads : 10
References:
1. Arthritis. National Institute of Arthritis and Musculoskeletal and Skin Diseases2019.
2. K.D.Tripathi, Essentials of Medical Pharmacology ,8th edition, page no.1467.
3. F.S.K.Barar ,Essentials of Pharmacotherapeutics, page no.117.
4. Gary C. Yee ,Joseph T. DiPiro ,Gary R.Matzke, Barbar G. Wells, L. Micheal Posey, Parmacotherapy A Pathophysiologic Approach, 9th edition, page no.1437.
5. Cronstein BN, Sunkureddi P. Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis. J Clin Rheumatol 2013;19(1):19-29.
6. Dar RA, Shahnawaz M, Rasool S Qazi PH. Natural product medicines: A literature update. J Phytopharm 2016;6(6):340-2.
7. Hunter DJ, Felson DT .Osteoarthritis. BMJ 2006;332(7542):63t9- 42.
8. Takahashi I, Matsuzaki T, Kuroki H, Hoso M. Induction of osteoarthritis by injecting monosodium iodoacetate into the patellofemoral joint of an experimental rat model. PLoS one 2018;13.
9. Xu Q, Zhang Z, Sun W. Effect of Naringin on Monosodium Iodoacetate-Induced Osteoarthritis Pain in Rats. Med Sci Monit 2017;23:3746-51.
10. Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Casp J Intern Med 2011;2(2):205-12.
11. Vina ER, Kwoh CK. Epidemiology of osteoarthritis:literature update. Curr Opin Rheumatol 2018;30(2):160-7.
12. Pal CP, Singh P, Chaturvedi S, Pruthi KK,Vi jA.Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop2016;50(5):518-22.
13. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014;28(1):5-15.
14. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol2006;16(4):197-205.
15. Attur MG, Dave M, Akamatsu M, Katoh M, Amin AR. Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage 2002;10(1):1-4.
16. Loeser RF. Molecular Mechanisms of Cartilage Destruction: Mechanics, Inflammatory Mediators and Aging Collide. Arthritis Rheum2006;54(5):1357-60.
17. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: A meta- analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901-7.
18. Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-Induced Hepatotoxicity: A Comprehensive Update. J ClinTranslHepatol2016;4(2):131-42.
19. Fokunang CN, Fokunang ET, Frederick K, Ngameni B, Ngadjui B. Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries. MOJ Toxicol2018;4(1):5-13.
20. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Dis 2018;9(1):143-50.
21. Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop2014;5(3):351-61.
22. Yavuz U, Sökücü S, Albayrak A, Oztürk K. Efficacy comparisons of the intra articular steroidal agents in the patients with knee osteoarthritis. Rheumatol Int 2012;32(11):3391-6.
23. Stein C, Baerwald C. Opioids for the treatment of arthritis pain. Expert Opin Pharmacother 2014;15(2):193-202.
24. Nakatani T. Opioid therapy and management of side effects associated with opioids. Gan To Kagaku Ryoho 2017;44(4):294-7.
25. Rymal E, Rizzolo D. Gout: A comprehensive review. JAAPA 2014;27(9):26-31.
26. Richette P, Bardin T. Gout. Lancet 2010;375(9711):318-28.
27. Sabina EP, Nagar S, Rasool M .A role of piperine on monosodium urate crystal-induced inflammation-an experimental model of gouty arthritis. Inflammation2011;34(3):184-92.
28. An J, Yang HJ, Park K, Lee J, Kim BW. Reparatory and preventive effects of oriental herb extract mixture (OHEM) on hyperuricemia and gout. Food Sci Biotechnol 2010;19:517-24.
29. Harris MD, Siegel LB, Alloway JA. Gout and Hyperuricemia. Am Fam Physician1999;59(4):925-34.
30. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol2015;11(11):649-62.
31. Saigal R, Agrawal A. Pathogenesis and Clinical Management of Gouty Arthritis. J Assoc Physicians India 2015;63(12):56- 63.
32. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther2010;12(2):206.
33. Ong KL, Wu BJ, Cheung BMY, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors and association with cardio vascular diseases in the United States, 1999 to 2008. Ann Epidemiol 2013;23(2):80-6.
34. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389 (10086):2338-48.
35. Dinesh P, Rasool M. uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. Pharmacol Res 2018;134:31-9.
36. MajithiaV, Geraci SA. Rheumatoid Arthritis: Diagnosis and Management. Am J Med2007;120(11):936-9.
37. Gibof sky A. Overview of epidemiology, pathophysiology and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295-302.
38. Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis. PeerJ 2017;5:e4035.
39. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004- 2014. Rheumatol Int 2017;37(9):1551-7
40. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County,Minnesota,1955-2007.Arthritis Rheum 2010;62(6):1576-82.
41. Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort(I). Mod Rheumatol 2014;24(1):33-40.
42. Fazal SA, Khan M, Nishi SE, Alam F, Zarin N, Bari MT, et al. A clinical update and global economic burden of rheumatoid arthritis.Endocr Metab Immune Disord Drug Targets 2018;18(2):98-109.
43. Orr CK, Najm A, Young F, Mc Garry T, Biniecka M, Fearon U, et al.The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med2018;5.
44. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018;6:15.
45. Firestein GS, Mc Innes IB. Immuno pathogenesis of Rheumatoid Arthritis. Immunity 2017;46(2):183-96.
46. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388(10055):2023-2038.
47. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.CurrRheumatol Rep2009;11(5):365-70.
48. Udhaya Lavinya B, Sangeetha N, Manisha P, Ramkumar K, Kavitha M, Evan Prince Sabina. Virtual screening of peptidyl arginine deiminase type 4 inhibiting potential of chosen flavonoids. Res J Pharm Technol 2018;11:753-7.
49. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther2013;15:S2.
50. Clarke L, Kirwan J. Efficacy, safety and mechanism ofaction of modified-release prednisone in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012;4(3):159-66.
51. Haraoui B, Jovaisas A, Bensen WG ,Faraawi R ,Kelsall J, Dixit S, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: Treatment implications based on a real-world Canadian population. RMD Open 2015;1(1):e000078.
52. Satyanarayanasetty D, Pawar K, Nadig P, Haran A. Multiple adverse effects of systemic corticosteroids: A case report. J Clin Diagn Res 2015;9(5):FD01-2.
53. Benjamin O, Lappin SL. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls2018.
54. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA 2018;320(13):1360-72.
55. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: Asystematic review. Eur J Med Chem 2018;158:502-16.
56. Joshi P, Dhaneshwar SS. An update on disease modifying antirheumatic drugs.Inflamm Allergy Drug Targets 2014;13(4):249-61.
57. Okoronkwo I, Onyia-pat JL, Okpala P, Agbo MA, Ndu A. Patterns of complementary and alternative medicine use, perceived benefits and adverse effects among adult users in Enugu Urban, Southeast Nigeria. Evid Based Complement Altern Med2014;2014.
58. Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E.Wilson(Houpo) and its constituents. J Zhejiang Univ Sci B.2017;18(3):194-214.
59. Chen YJ, Tsai KS, Chan DC, Lan KC, Chen CF, Yang RS, et al. Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes. J Orthop Res 2014;32(4):573-80.
60. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med2010;52:55-62.
61. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase- induced rabbit osteoarthritis model. Osteoarthritis Cartilage 2002;10(6):471-8.
62. Mahboob N, Sousan K, Shirzad A, Amir G, Mohammad V,Reza M, et al. The efficacy of a topical gel prepared using lake urmia mud in patients with knee osteoarthritis. JAltern Complement Med 2009;15(11):1239-42.
63. Hashempur MH, Sadrneshin S, Mosavat SH, Ashraf A. Green tea (Camellia sinensis) for patients with knee osteoarthritis: A randomized open-label active-controlled clinical trial. ClinNutr2018;37(1):85-90.
64. Zhao Y, Li Z, Wang W, Zhang H, Chen J, Su P, et al. Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway. Inflammation 2016;39(1):385-92.
65. Pan T,Wu D,Cai N,Chen R,Shi X, LiB, et al. Alpha-Mangostin protects rat articular chondrocytes against IL-1β-induced inflammation and slows the progression of osteoarthritis in a rat model. Int Immunopharmacol 2017;52:34-43.
66. Wang SN, XieGP, Qin CH, Chen YR, Zhang KR, Li X, et al. Aucubin prevents interleukin-1beta induced inflammation and cartilage matrix degradation via inhibition of NF-κBsignaling pathway in rat articular chondrocytes. Int Immunopharmacol 2015;24(2):408-15.
67. Wang Z, Huang J, Zhou S, Luo F, Xu W, Wang Q, et al. Anemonin attenuates osteoarthritis progression through inhibiting the activation of IL-1β/NF-κB pathway. J Cell Mol Med 2017;21(12):3231-43.
68. Lou Y, Wang C, ZhengW, Tang Q, Chen Y, Zhang X, et al. Salvianolic acid B inhibits IL-1β-induced inflammatory cytokine production in human osteoarthritis chondrocytes and has a protective effect in a mouse osteoarthritis model. Int Immunopharmacol 2017;46:31-7.
69. Kiyani MM, Sohail MF, Shahnaz G, Rehman H, Akhtar MF, Nawaz I, et al. Evaluation of turmeric nanoparticles as anti- gout agent: Modernization of a traditional drug. Medicina 2019;55(1):10.
70. Yin J, RenW, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol2018;9:1697.
71. Ferraz-Filha ZS, Michel Araújo MC de P, Ferrari FC, Dutra IPAR, Saúde-Guimarães DA. Tabebuiaroseoalba: In vivo hypouricemic and anti-inflammatory effects of its ethanolic extract and constituents. Planta Med2016;82(16):1395-402.
72. Li L, TengM, Liu Y, QuY, Zhang Y, Lin F, et al. Anti- Gouty arthritis and antihyperuricemia effects of sunflower (Helianthus annuus) head extract in gouty and hyperuricemia animal models. BioMed Res Int 2017;2017:5852076.
73. Sabina EP, Rasool M. An invivo and invitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice.Vascul Pharmacol2008;48(1):14-20.
74. Huang J, Zhu M, Tao Y, Wang S, Chen J, Sun W, et al. Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat. J Pharm Pharmacol 2012;64(8):1119-27.
75. Peter SJ, Katturaja R, Namachivayam A, Nithyanandham S, Parthasarathy M, Sabina EP. Anti-inflammatory potential of the aqueous extract of Cyamopsis tetragonoloba against the MSU-induced arthritis in female Wistar albino rats. Asian Pac J Mol Biol Biotechnol 2020;28:1-12.
76. Rasool M, VaralakshmiP. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol 2007;21(2):157-64.
77. Gupta A, Singh S. Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol 2014;52(3):308-20.
78. Sun CL, Wei J, Bi LQ. Rutin attenuates oxidative stress and proinflammatory cytokine level in adjuvant induced rheumatoid arthritis via inhibition of NF-κB. Pharmacology 2017;100:40-9.
79. Liu XY, Xu L, Wang Y, Li JX, Zhang Y, Zhang C, et al. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/ NF-κB pathway. Int Immunopharmacol2017;44:105-14.
80. Ushiro S, Ono M, Nakayama J, FugiwaraT, Komatsu Y, Sugimachi K, et al. New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization. Int J Cancer 1997;72(4):657-63.
81. Kumar VL, Roy S. Calotropis procera latex extract affords protection against inflammation and oxidative stress in freund’s complete adjuvant-induced monoarthritis in rats. Mediators Inflamm 2007;2007:47523.
82. Zhuang Y, Liu J, Ma P, Bai J, Ding Y, Yang H, et al. Tamarixinin A alleviates joint destruction of rheumatoid arthritis by blockade of MAPK and NF-κB activation. Front Pharmacol 2017;8.
83. Shabbir A, Batool SA, Basheer MI, Shahzad M, Sultana K, Tareen RB, et al. Ziziphora clinopodioides ameliorated rheumatoid arthritis and inflammatory paw edema in different models of acute and chronic inflammation. Biomed Pharmacother2018;97:1710-21.
84. Sudaroli M, Chatterjee TK. Evaluation of red and white seed extracts of Abrus precatorius Linn. Against freunds complete adjuvant induced arthritis in rats.J Med Plants Res 2007;1:086- 94.
85. Coelho MGP, Reis PA, Gava VB ,Marques PR, Gayer CR, Laranja GAT, et al. Anti-arthritic effect and subacute toxicological evaluation of Baccharis genistelloides aqueous extract. Toxicol Lett 2004;154:69-80.
86. Semalty M, Semalty A, Badola A, Joshi GP, Rawat MSM. Semecarpus anacardium Linn: A review. Pharmacogn Rev 2010;4:88-94.
87. Zhao Y, Li Z, Wang W, Zhang H, Chen J, Su P, et al. Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway. Inflammation 2016;39(1):385-92.
88. Pan T, Wu D, Cai N, Chen R, Shi X, Li B, et al. Alpha-Mangostin protects rat articular chondrocytes against IL-1β-induced inflammation and slows the progression of osteoarthritis in a rat model. Int Immunopharmacol 2017;52:34-43.
89. Wang Z, Huang J, Zhou S, Luo F, Xu W, Wang Q, et al. Anemonin attenuates osteoarthritis progression through inhibiting the activation of IL-1β/NF-κB pathway. J Cell Mol Med2017;21:3231-43.
90. Lou Y, Wang C, Zheng W, Tang Q, Chen Y, Zhang X, et al. Salvianolic acid B inhibits IL-1β-induced inflammatory cytokine production in human osteoarthritis chondrocytes and has a protective effect in a mouse osteoarthritis model. Int Immunopharmacol 2017;46:31-7.
91. Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol 2018;9:1697.
92. Peter SJ, Katturaja R, Namachivayam A, Nithyanandham S, Parthasarathy M, Sabina EP. Anti-inflammatory potential of the aqueous extract of Cyamopsis tetragonoloba against the MSU-induced arthritis in female Wistar albino rats J.AsianPac J Mol Biol Biotechnol 2020;28(3):1-12.
93. Rasool M, VaralakshmiP. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol 2007;21(2):157-64.
2. K.D.Tripathi, Essentials of Medical Pharmacology ,8th edition, page no.1467.
3. F.S.K.Barar ,Essentials of Pharmacotherapeutics, page no.117.
4. Gary C. Yee ,Joseph T. DiPiro ,Gary R.Matzke, Barbar G. Wells, L. Micheal Posey, Parmacotherapy A Pathophysiologic Approach, 9th edition, page no.1437.
5. Cronstein BN, Sunkureddi P. Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis. J Clin Rheumatol 2013;19(1):19-29.
6. Dar RA, Shahnawaz M, Rasool S Qazi PH. Natural product medicines: A literature update. J Phytopharm 2016;6(6):340-2.
7. Hunter DJ, Felson DT .Osteoarthritis. BMJ 2006;332(7542):63t9- 42.
8. Takahashi I, Matsuzaki T, Kuroki H, Hoso M. Induction of osteoarthritis by injecting monosodium iodoacetate into the patellofemoral joint of an experimental rat model. PLoS one 2018;13.
9. Xu Q, Zhang Z, Sun W. Effect of Naringin on Monosodium Iodoacetate-Induced Osteoarthritis Pain in Rats. Med Sci Monit 2017;23:3746-51.
10. Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Casp J Intern Med 2011;2(2):205-12.
11. Vina ER, Kwoh CK. Epidemiology of osteoarthritis:literature update. Curr Opin Rheumatol 2018;30(2):160-7.
12. Pal CP, Singh P, Chaturvedi S, Pruthi KK,Vi jA.Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop2016;50(5):518-22.
13. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014;28(1):5-15.
14. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol2006;16(4):197-205.
15. Attur MG, Dave M, Akamatsu M, Katoh M, Amin AR. Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage 2002;10(1):1-4.
16. Loeser RF. Molecular Mechanisms of Cartilage Destruction: Mechanics, Inflammatory Mediators and Aging Collide. Arthritis Rheum2006;54(5):1357-60.
17. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: A meta- analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901-7.
18. Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-Induced Hepatotoxicity: A Comprehensive Update. J ClinTranslHepatol2016;4(2):131-42.
19. Fokunang CN, Fokunang ET, Frederick K, Ngameni B, Ngadjui B. Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries. MOJ Toxicol2018;4(1):5-13.
20. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Dis 2018;9(1):143-50.
21. Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop2014;5(3):351-61.
22. Yavuz U, Sökücü S, Albayrak A, Oztürk K. Efficacy comparisons of the intra articular steroidal agents in the patients with knee osteoarthritis. Rheumatol Int 2012;32(11):3391-6.
23. Stein C, Baerwald C. Opioids for the treatment of arthritis pain. Expert Opin Pharmacother 2014;15(2):193-202.
24. Nakatani T. Opioid therapy and management of side effects associated with opioids. Gan To Kagaku Ryoho 2017;44(4):294-7.
25. Rymal E, Rizzolo D. Gout: A comprehensive review. JAAPA 2014;27(9):26-31.
26. Richette P, Bardin T. Gout. Lancet 2010;375(9711):318-28.
27. Sabina EP, Nagar S, Rasool M .A role of piperine on monosodium urate crystal-induced inflammation-an experimental model of gouty arthritis. Inflammation2011;34(3):184-92.
28. An J, Yang HJ, Park K, Lee J, Kim BW. Reparatory and preventive effects of oriental herb extract mixture (OHEM) on hyperuricemia and gout. Food Sci Biotechnol 2010;19:517-24.
29. Harris MD, Siegel LB, Alloway JA. Gout and Hyperuricemia. Am Fam Physician1999;59(4):925-34.
30. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol2015;11(11):649-62.
31. Saigal R, Agrawal A. Pathogenesis and Clinical Management of Gouty Arthritis. J Assoc Physicians India 2015;63(12):56- 63.
32. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther2010;12(2):206.
33. Ong KL, Wu BJ, Cheung BMY, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors and association with cardio vascular diseases in the United States, 1999 to 2008. Ann Epidemiol 2013;23(2):80-6.
34. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389 (10086):2338-48.
35. Dinesh P, Rasool M. uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. Pharmacol Res 2018;134:31-9.
36. MajithiaV, Geraci SA. Rheumatoid Arthritis: Diagnosis and Management. Am J Med2007;120(11):936-9.
37. Gibof sky A. Overview of epidemiology, pathophysiology and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295-302.
38. Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis. PeerJ 2017;5:e4035.
39. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004- 2014. Rheumatol Int 2017;37(9):1551-7
40. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County,Minnesota,1955-2007.Arthritis Rheum 2010;62(6):1576-82.
41. Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort(I). Mod Rheumatol 2014;24(1):33-40.
42. Fazal SA, Khan M, Nishi SE, Alam F, Zarin N, Bari MT, et al. A clinical update and global economic burden of rheumatoid arthritis.Endocr Metab Immune Disord Drug Targets 2018;18(2):98-109.
43. Orr CK, Najm A, Young F, Mc Garry T, Biniecka M, Fearon U, et al.The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med2018;5.
44. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018;6:15.
45. Firestein GS, Mc Innes IB. Immuno pathogenesis of Rheumatoid Arthritis. Immunity 2017;46(2):183-96.
46. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388(10055):2023-2038.
47. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.CurrRheumatol Rep2009;11(5):365-70.
48. Udhaya Lavinya B, Sangeetha N, Manisha P, Ramkumar K, Kavitha M, Evan Prince Sabina. Virtual screening of peptidyl arginine deiminase type 4 inhibiting potential of chosen flavonoids. Res J Pharm Technol 2018;11:753-7.
49. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther2013;15:S2.
50. Clarke L, Kirwan J. Efficacy, safety and mechanism ofaction of modified-release prednisone in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012;4(3):159-66.
51. Haraoui B, Jovaisas A, Bensen WG ,Faraawi R ,Kelsall J, Dixit S, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: Treatment implications based on a real-world Canadian population. RMD Open 2015;1(1):e000078.
52. Satyanarayanasetty D, Pawar K, Nadig P, Haran A. Multiple adverse effects of systemic corticosteroids: A case report. J Clin Diagn Res 2015;9(5):FD01-2.
53. Benjamin O, Lappin SL. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls2018.
54. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA 2018;320(13):1360-72.
55. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: Asystematic review. Eur J Med Chem 2018;158:502-16.
56. Joshi P, Dhaneshwar SS. An update on disease modifying antirheumatic drugs.Inflamm Allergy Drug Targets 2014;13(4):249-61.
57. Okoronkwo I, Onyia-pat JL, Okpala P, Agbo MA, Ndu A. Patterns of complementary and alternative medicine use, perceived benefits and adverse effects among adult users in Enugu Urban, Southeast Nigeria. Evid Based Complement Altern Med2014;2014.
58. Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E.Wilson(Houpo) and its constituents. J Zhejiang Univ Sci B.2017;18(3):194-214.
59. Chen YJ, Tsai KS, Chan DC, Lan KC, Chen CF, Yang RS, et al. Honokiol, a low molecular weight natural product, prevents inflammatory response and cartilage matrix degradation in human osteoarthritis chondrocytes. J Orthop Res 2014;32(4):573-80.
60. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med2010;52:55-62.
61. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase- induced rabbit osteoarthritis model. Osteoarthritis Cartilage 2002;10(6):471-8.
62. Mahboob N, Sousan K, Shirzad A, Amir G, Mohammad V,Reza M, et al. The efficacy of a topical gel prepared using lake urmia mud in patients with knee osteoarthritis. JAltern Complement Med 2009;15(11):1239-42.
63. Hashempur MH, Sadrneshin S, Mosavat SH, Ashraf A. Green tea (Camellia sinensis) for patients with knee osteoarthritis: A randomized open-label active-controlled clinical trial. ClinNutr2018;37(1):85-90.
64. Zhao Y, Li Z, Wang W, Zhang H, Chen J, Su P, et al. Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway. Inflammation 2016;39(1):385-92.
65. Pan T,Wu D,Cai N,Chen R,Shi X, LiB, et al. Alpha-Mangostin protects rat articular chondrocytes against IL-1β-induced inflammation and slows the progression of osteoarthritis in a rat model. Int Immunopharmacol 2017;52:34-43.
66. Wang SN, XieGP, Qin CH, Chen YR, Zhang KR, Li X, et al. Aucubin prevents interleukin-1beta induced inflammation and cartilage matrix degradation via inhibition of NF-κBsignaling pathway in rat articular chondrocytes. Int Immunopharmacol 2015;24(2):408-15.
67. Wang Z, Huang J, Zhou S, Luo F, Xu W, Wang Q, et al. Anemonin attenuates osteoarthritis progression through inhibiting the activation of IL-1β/NF-κB pathway. J Cell Mol Med 2017;21(12):3231-43.
68. Lou Y, Wang C, ZhengW, Tang Q, Chen Y, Zhang X, et al. Salvianolic acid B inhibits IL-1β-induced inflammatory cytokine production in human osteoarthritis chondrocytes and has a protective effect in a mouse osteoarthritis model. Int Immunopharmacol 2017;46:31-7.
69. Kiyani MM, Sohail MF, Shahnaz G, Rehman H, Akhtar MF, Nawaz I, et al. Evaluation of turmeric nanoparticles as anti- gout agent: Modernization of a traditional drug. Medicina 2019;55(1):10.
70. Yin J, RenW, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol2018;9:1697.
71. Ferraz-Filha ZS, Michel Araújo MC de P, Ferrari FC, Dutra IPAR, Saúde-Guimarães DA. Tabebuiaroseoalba: In vivo hypouricemic and anti-inflammatory effects of its ethanolic extract and constituents. Planta Med2016;82(16):1395-402.
72. Li L, TengM, Liu Y, QuY, Zhang Y, Lin F, et al. Anti- Gouty arthritis and antihyperuricemia effects of sunflower (Helianthus annuus) head extract in gouty and hyperuricemia animal models. BioMed Res Int 2017;2017:5852076.
73. Sabina EP, Rasool M. An invivo and invitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice.Vascul Pharmacol2008;48(1):14-20.
74. Huang J, Zhu M, Tao Y, Wang S, Chen J, Sun W, et al. Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat. J Pharm Pharmacol 2012;64(8):1119-27.
75. Peter SJ, Katturaja R, Namachivayam A, Nithyanandham S, Parthasarathy M, Sabina EP. Anti-inflammatory potential of the aqueous extract of Cyamopsis tetragonoloba against the MSU-induced arthritis in female Wistar albino rats. Asian Pac J Mol Biol Biotechnol 2020;28:1-12.
76. Rasool M, VaralakshmiP. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol 2007;21(2):157-64.
77. Gupta A, Singh S. Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol 2014;52(3):308-20.
78. Sun CL, Wei J, Bi LQ. Rutin attenuates oxidative stress and proinflammatory cytokine level in adjuvant induced rheumatoid arthritis via inhibition of NF-κB. Pharmacology 2017;100:40-9.
79. Liu XY, Xu L, Wang Y, Li JX, Zhang Y, Zhang C, et al. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/ NF-κB pathway. Int Immunopharmacol2017;44:105-14.
80. Ushiro S, Ono M, Nakayama J, FugiwaraT, Komatsu Y, Sugimachi K, et al. New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization. Int J Cancer 1997;72(4):657-63.
81. Kumar VL, Roy S. Calotropis procera latex extract affords protection against inflammation and oxidative stress in freund’s complete adjuvant-induced monoarthritis in rats. Mediators Inflamm 2007;2007:47523.
82. Zhuang Y, Liu J, Ma P, Bai J, Ding Y, Yang H, et al. Tamarixinin A alleviates joint destruction of rheumatoid arthritis by blockade of MAPK and NF-κB activation. Front Pharmacol 2017;8.
83. Shabbir A, Batool SA, Basheer MI, Shahzad M, Sultana K, Tareen RB, et al. Ziziphora clinopodioides ameliorated rheumatoid arthritis and inflammatory paw edema in different models of acute and chronic inflammation. Biomed Pharmacother2018;97:1710-21.
84. Sudaroli M, Chatterjee TK. Evaluation of red and white seed extracts of Abrus precatorius Linn. Against freunds complete adjuvant induced arthritis in rats.J Med Plants Res 2007;1:086- 94.
85. Coelho MGP, Reis PA, Gava VB ,Marques PR, Gayer CR, Laranja GAT, et al. Anti-arthritic effect and subacute toxicological evaluation of Baccharis genistelloides aqueous extract. Toxicol Lett 2004;154:69-80.
86. Semalty M, Semalty A, Badola A, Joshi GP, Rawat MSM. Semecarpus anacardium Linn: A review. Pharmacogn Rev 2010;4:88-94.
87. Zhao Y, Li Z, Wang W, Zhang H, Chen J, Su P, et al. Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway. Inflammation 2016;39(1):385-92.
88. Pan T, Wu D, Cai N, Chen R, Shi X, Li B, et al. Alpha-Mangostin protects rat articular chondrocytes against IL-1β-induced inflammation and slows the progression of osteoarthritis in a rat model. Int Immunopharmacol 2017;52:34-43.
89. Wang Z, Huang J, Zhou S, Luo F, Xu W, Wang Q, et al. Anemonin attenuates osteoarthritis progression through inhibiting the activation of IL-1β/NF-κB pathway. J Cell Mol Med2017;21:3231-43.
90. Lou Y, Wang C, Zheng W, Tang Q, Chen Y, Zhang X, et al. Salvianolic acid B inhibits IL-1β-induced inflammatory cytokine production in human osteoarthritis chondrocytes and has a protective effect in a mouse osteoarthritis model. Int Immunopharmacol 2017;46:31-7.
91. Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol 2018;9:1697.
92. Peter SJ, Katturaja R, Namachivayam A, Nithyanandham S, Parthasarathy M, Sabina EP. Anti-inflammatory potential of the aqueous extract of Cyamopsis tetragonoloba against the MSU-induced arthritis in female Wistar albino rats J.AsianPac J Mol Biol Biotechnol 2020;28(3):1-12.
93. Rasool M, VaralakshmiP. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol 2007;21(2):157-64.